Earnings Releases·Nov 4, 2026, 4:38 PM ET

STERIS — Fiscal 2027 Second Quarter Earnings Summary

Total revenue increased 9% year-over-year to $1.6 billion, with constant currency organic growth of 8%; adjusted net income rose to $286.8 million ($2.94 per diluted share) from $244.5 million ($2.47 per diluted share) in the prior year period.
Fiscal 2027 adjusted earnings per share guidance was raised to $11.35–$11.55 (from $11.10–$11.30) to reflect approximately $0.18 in tariff refund benefits, while full-year revenue growth expectations remain unchanged at 7–8% as reported.
Capital allocation included $215.9 million in share repurchases and a dividend increase to $0.69 per share over the first six months, alongside a new restructuring plan targeting $9 million in annualized savings.
Segment performance was driven by Life Sciences (18% revenue growth) and Healthcare (9% growth), while Applied Sterilization Technologies grew 5%; the company also plans to discontinue backlog disclosures starting Fiscal 2028.
Future outlook remains positive with projected Fiscal 2027 free cash flow of approximately $800 million and operating cash flow of $1,250 million, pending the regulatory closing of the proposed Xodus Medical acquisition.